ApexOnco Front Page Recent articles 22 May 2026 ASCO 2026 preview – Pumitamig looks similar to ivonescimab again First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story. 22 May 2026 ASCO 2026 preview – Black Diamond tries to catch up with Arrivent Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry. 10 November 2025 SITC 2025 – fresh hope for Summit's Harmoni Harmoni-A hits, backing a quiet disclosure about the Harmoni trial. 7 November 2025 BeOne joins the Kat6 pack BG-75202 features among several projects starting first-in-human trials. 7 November 2025 An ozekibart reminder about liver toxicity Inhibrx reveals three deaths in phase 1, but all predate screening protocols. 6 November 2025 Pfizer moves into the VEGF bispecific fast lane There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials. 5 November 2025 Venture capitalists buy into TROP2 Blackstone follows Abingworth, but why? 5 November 2025 One of Adcetris’s twin sons strikes out Pfizer cans PF-08046045, but keeps PF-08046044 for now. Load More Recent Quick take Repare shelves its early work 29 August 2024 Two Keytruda setbacks in early cancer settings 29 August 2024 Bayer buys into NextRNA 28 August 2024 World Lung 2024 preview – the pressure is on for Summit 27 August 2024 Confirming Nuvation’s AnHeart takeover 22 August 2024 PTK7 seems key for Kelun 21 August 2024 Kineta is down, but not yet out 20 August 2024 Tissue factor tempts Adcendo 20 August 2024 J&J gets its first broad Rybrevant nod 20 August 2024 Dosing limit solves BioNTech's clinical hold 19 August 2024 Load More Most Popular